EB
ALXN

Eastern Bank’s Alexion Pharmaceuticals ALXN Stock Holding History

Eastern Bank’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,000
Closed -$245K – 217
2016
Q4 		$245K Hold
2,000
– – 0.02% 180
2016
Q3 		$245K Hold
2,000
– – 0.02% 179
2016
Q2 		$234K Hold
2,000
– – 0.02% 191
2016
Q1 		$278K Hold
2,000
– – 0.02% 172
2015
Q4 		$382K Hold
2,000
– – 0.03% 155
2015
Q3 		$313K Hold
2,000
– – 0.03% 166
2015
Q2 		$362K Hold
2,000
– – 0.03% 155
2015
Q1 		$347K Hold
2,000
– – 0.03% 159
2014
Q4 		$370K Hold
2,000
– – 0.03% 164
2014
Q3 		$332K Hold
2,000
– – 0.03% 166
2014
Q2 		$313K Hold
2,000
– – 0.03% 175
2014
Q1 		$304K Buy
+2,000
New +$318K 0.03% 178

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Eastern Bank's ALXN Position: Q1 2017 in Review

Eastern Bank sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 2,000 shares — an estimated $245K sold.

Eastern Bank first reported a position in ALXN in Q1 2014 and held it in 12 quarters. The position peaked at $382K in Q4 2015. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Eastern Bank reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Eastern Bank sold 2,000 Alexion Pharmaceuticals shares in Q1 2017, an estimated $245K.
  • Eastern Bank first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 12 quarters.
  • Eastern Bank's Alexion Pharmaceuticals position peaked at $382K in Q4 2015.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Eastern Bank's 13F filing for Q1 2017, filed 17 Apr 2017.